Market based hints on cancerI ahve posted a list of hints regarding the potential positive outcome of the phase 1a cancer trial. These were laregely based off of what the company has said in general terms about the trial and other actions they have taken that highlight they are now focusing on their cancer program as TH's lead asset. But the market is also offering some hints as well. First, the stock has greatly outperformed the sagging biotech indix this year. Second, there is almost no short interest in THTX. Third, the open interest in the new options trading on THTX is almost entirely on the call side.
While we don't know the outcome of the phase 1a cancer trial yet, the market is also hinting the results are expected to be worthwhile.